GSK publishes Q3 2026 results call transcript
GSK•GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, and a 5% increase in core operating profit. It reaffirmed full-year guidance, expecting sales and core operating profit in the upper half of their ranges.
1. Quarterly results
GSK held its third-quarter 2026 results call on October 28, with CEO Luke Miels, CFO Julie Brown, Tony Wood and Nina Mojas attending. Sales rose 5% to £8.9 billion at constant exchange rates, while core operating profit increased 5%.
2. Outlook and costs
Management reaffirmed full-year guidance, expecting sales and core operating profit in the upper half of their ranges. Restructuring charges could reach £1 billion this year, and Brown indicated 2027 interest costs of £900 million to £1 billion.
3. HIV prevention data
Four-monthly HIV prevention data remain under analysis, with regulatory submission expected before year-end. Management maintained there was no read-through to treatment.
